Why Do Foreign Biotech and Pharma Companies Struggle to Hire US Leadership?
- Philip Lamb
- 10 hours ago
- 7 min read
The United States is the market every foreign biotech and pharmaceutical company eventually has to win, and it is also the market where their first leadership hire most often goes wrong. A German device maker can stumble on its first US general manager and recover. A foreign biotech that puts the wrong leader in front of the FDA, the Boston talent market, and American investors at the same time can lose years it does not have.
We see the same pattern repeatedly: a company with excellent science, real funding, and a proven leadership team at home enters the US and discovers that none of the assumptions that built the home operation survive the trip. The talent is priced differently, motivated differently, and concentrated in places the home office has never visited. This post explains the specific mechanics of why that happens and what the companies that get it right do differently.
Why Do Foreign Biotech and Pharma Companies Struggle to Hire US Leadership?
Foreign biotech and pharma companies struggle to hire US leadership because the three things that define the US life sciences market, equity-driven compensation, extreme geographic concentration of talent, and the FDA regulatory pathway, have no equivalent in most home markets, so the hiring playbook that built the company at home fails on all three at once. A hiring process calibrated for Munich, Osaka, or Seoul assumes salary-led compensation, a national talent pool, and a regulatory environment the leadership team already knows. The US inverts all three assumptions simultaneously, and the first leadership search is usually where the company finds out.
Foreign-owned companies are not marginal players in the American economy. Foreign affiliates employ roughly 8.66 million people in the United States according to the Bureau of Economic Analysis, and life sciences is one of the sectors where that investment keeps accelerating. The demand side is crowded, which means a foreign biotech is not just adapting to an unfamiliar market. It is competing for leadership talent against American companies that already speak the market's language, and against other foreign entrants who learned these lessons on their first attempt.
This is the same category of mistake we documented in what foreign companies get wrong when hiring their first US executive, but biotech and pharma concentrate the difficulty. In most industries a wrong first hire costs a company time and money. In life sciences it can cost a clinical program its credibility.
What Makes US Biotech and Pharma Talent Different From Other Industries?
US biotech and pharma talent is different from other industries because senior leaders evaluate opportunities primarily on the science, the funding runway, and the equity upside, not on base salary, and because the talent pool is concentrated in a handful of hub markets where every strong candidate already has competing options. A senior executive in Boston or the Philadelphia corridor is not comparing your offer against a generic industry salary survey. They are comparing your pipeline, your data, and your cap table against the three other companies recruiting them this quarter.
Equity is the first structural surprise. In US life sciences, meaningful equity participation is standard at the leadership level, and candidates read its absence as a signal that the US operation is a branch office rather than a real commitment. Foreign parent companies, especially family-owned European firms and large Asian corporates, often have no mechanism for granting US-style equity at all. The result is an offer that looks generous by home-market standards and lands as uncompetitive in Cambridge or San Diego. The compensation conversation has to be solved before the search starts, not discovered during the final negotiation.
Geographic concentration is the second. American life sciences leadership clusters in Boston, the San Francisco Bay Area, San Diego, the New Jersey and Philadelphia pharma corridor, and Research Triangle Park. We covered the mechanics of one of these markets in our look at Philadelphia's pharma and healthcare corridor, and the lesson generalizes: each hub has its own networks, its own reference chains, and its own compensation reality. A foreign company that opens its US office where real estate is cheap, then tries to recruit senior pharma leadership to it, has created a handicap no search firm can fully overcome.
The third difference is what candidates are walking away from. The strongest US life sciences executives are almost always employed, vested, and mid-vesting on equity that a move would forfeit. Recruiting them means buying out what they leave behind, which is a concept many foreign parents have never had to price into a hiring budget.
"Victorious warriors win first and then go to war, while defeated warriors go to war first and then seek to win." — Sun Tzu
The companies that win their first US leadership search win it before the search begins: the equity mechanism approved, the hub chosen, the buyout budgeted. The ones that struggle are trying to solve those questions candidate by candidate, in the middle of negotiations, while their best prospects take other offers.
What Do FDA and Regulatory Realities Mean for a First US Leadership Hire?
FDA and regulatory realities mean that a foreign biotech or pharma company's first US leader must carry credible, firsthand FDA experience, because the agency's expectations, timelines, and communication style cannot be learned from home-market regulatory work, and investors and partners will judge the US operation by whether its leadership has walked that path before. EMA experience, PMDA experience, or MFDS experience is real expertise, but it does not transfer one to one. US regulatory strategy is its own discipline, and everyone the new US operation needs to convince, from investors to clinical partners to eventual acquirers, knows it.
This changes the shape of the first hire in a way many foreign boards do not expect. In most industries, a first US leader is a commercial general manager. In life sciences, the first leadership hire is often someone who can stand in front of the FDA and in front of American partners with a track record both audiences recognize: a US-experienced chief medical officer, a head of regulatory affairs, or a general manager whose resume includes successful interaction with the agency. The commercial buildout can follow. The regulatory credibility cannot.
This is the same industry-specific depth argument we made about what makes executive search for a medical device company different from every other manufacturing search, where FDA QMSR and ISO 13485 fluency separate real candidates from plausible-sounding ones. In biopharma the equivalent filter is clinical and regulatory scar tissue. A candidate who has taken a program through an FDA advisory committee meeting is a fundamentally different asset than one who has managed a filing from a distance, and only a search process built by people who know the difference will reliably tell them apart. Our work with Pittsburgh medical device manufacturers hiring at the C-suite level runs into the same distinction constantly: the resume says regulatory experience, and the interview has to establish what kind.
In more than 30 years of retained search, we have found that foreign companies consistently underweight regulatory credibility and overweight home-office trust when they scope their first US leadership role. The instinct is to send a trusted executive from headquarters or hire someone who interviews comfortably in the parent company's culture. The searches that succeed flip that priority: they hire the person American regulators, investors, and partners will trust, then build the headquarters relationship around that person deliberately.
How Should a Foreign Biotech or Pharma Company Structure Its First US Leadership Search?
A foreign biotech or pharma company should structure its first US leadership search by making three decisions before contacting a single candidate: which US hub the operation will live in, how equity or its equivalent will work for US leadership, and whether the first hire is a regulatory-credible leader or a commercial one. Those three decisions determine which candidates are realistic, and skipping them means running a search that discovers its own constraints one lost candidate at a time.
The hub decision comes first because it prices everything else. The equity decision comes second because it determines whether the strongest candidates will engage at all, and because inventing a workaround, a phantom equity plan, a long-term cash incentive that mimics vesting, takes months of board and legal work that cannot be compressed once a finalist is waiting. The role-shape decision comes third, and it should be made with an honest reading of what the next 24 months actually require: if there is a filing, a trial, or a partnership negotiation in that window, regulatory credibility leads.
The full playbook for the corporate side of this, entity setup, sequencing, and how the first leadership team gets built around the first hire, is in our cornerstone guide on how a foreign company sets up and staffs its first US operation. And the pattern is not unique to life sciences: the same discipline shows up in how Japanese companies hire senior leaders when expanding into the United States, where title-versus-authority mismatches quietly kill first hires. Biotech simply raises the stakes and shortens the forgiveness window.
PRL International is a retained executive search firm serving Pittsburgh and Western Pennsylvania and working with international companies entering the US market, specializing in senior-level placements in energy, manufacturing, life sciences, and mid-market companies. The foreign life sciences companies that get this right treat the first US leadership hire as the single most important decision of the expansion, because it is. The science gets a company to the American market. The leader determines whether the American market ever finds out.
For a broader look at how we run these engagements, visit our international executive search practice overview.
If you are ready to fill a senior role or want to talk through your search, reach out at prlinternational.com/contact
Want to know what questions to ask before hiring a search firm? Download the free 7-Question Guide: https://prl-proposal.vercel.app/guide
Comments